Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses Meeting Abstract
| Authors: | Tempero, M. A.; Reni, M.; Riess, H.; O'Reilly, E. M.; Krishnamurthi, S.; Österlund, P.; Ales-Diaz, I. C.; Milella, M.; Siena, S.; Tabernero, J.; Van Cutsem, E.; Philip, P. A.; Goldstein, D.; Berlin, J. D.; Li, M.; Ferrara, S.; Le Bruchec, Y.; McGovern, D.; Biankin, A. |
| Abstract Title: | Phase III, international, multicenter, randomized, open-label trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for surgically resected pancreatic adenocarcinoma (APACT): Subgroup analyses |
| Meeting Title: | 44th ESMO Congress (ESMO 2019) |
| Journal Title: | Annals of Oncology |
| Volume: | 30 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2019 Sep 27-Oct 1 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2019-10-01 |
| Start Page: | mdz247.010 |
| Language: | English |
| ACCESSION: | WOS:000491295502112 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdz247.010 |
| Notes: | Meeting Abstract: 682P -- Appears on pages v259-v260 of the abstract book -- Source: Wos |
